文献速递皮肤肿瘤

CP-GEP模型在原发皮肤黑色素瘤前哨淋巴结转移中的验证

Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
PubMed 文献 · Br J Dermatol · 2020-11-02

本研究在荷兰Erasmus医学中心癌症研究所2007–2017年间接受前哨淋巴结活检(SLNB)的210例原发皮肤黑色素瘤患者中验证CP-GEP模型。该模型结合年龄、Breslow厚度及8个转移相关基因表达,以SLNB病理为金标准。结论提示该模型可辅助识别低危患者、有望减少SLNB。

要点

  • 所有T4期黑色素瘤均被CP-GEP判为高风险,未评估低危可能。

核心结论

  • CP-GEP模型是一种非侵入性且经外部验证的工具,能准确识别原发皮肤黑色素瘤中前哨淋巴结转移低风险的患者。
  • 在该验证队列中,CP-GEP模型显示出减少黑色素瘤患者SLNB操作的潜力。

研究设计与样本

  • 研究为独立荷兰队列验证,纳入2007–2017年间在Erasmus医学中心癌症研究所接受SLNB的≥18岁原发皮肤黑色素瘤患者,共210例。
  • CP-GEP模型结合临床病理特征(年龄和Breslow厚度)与8个黑色素瘤转移相关基因(ITGB3、PLAT、SERPINE2、GDF15、TGFBR1、LOXL4、CXCL8和MLANA)的表达。
  • 以前哨淋巴结活检病理结果为金标准,计算CP-GEP模型的高风险或低风险性能指标。

主要发现

  • 210例患者中,T2期94例(45%)、T3期70例(33%)最常见。
  • 全部患者中27%(56例)SLNB阳性;T1、T2、T3、T4期患者淋巴结转移率分别为0%、30%、54%、16%。
  • 所有T4期黑色素瘤均被CP-GEP判为高风险。

关键数值与推荐

  • CP-GEP模型输出高风险或低风险以预测淋巴结转移,低风险对应阴性预测值。
  • CP-GEP对T4期黑色素瘤均指示高风险。

临床怎么用

  • 对于T1–T3期原发皮肤黑色素瘤患者,CP-GEP模型可辅助识别前哨淋巴结转移低风险者,有望减少SLNB操作。
  • T4期黑色素瘤均被模型判为高风险,不宜依据该模型降级处理。
  • 临床应用需结合SLNB金标准及患者个体情况综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Clinicopathological and Gene Expression Profile (CP-GEP) model was developed to accurately identify patients with T1-T3 primary cutaneous melanoma at low risk for nodal metastasis. OBJECTIVES: To validate the CP-GEP model in an independent Dutch cohort of patients with melanoma. METHODS: Patients (aged ≥ 18 years) with primary cutaneous melanoma who underwent sentinel lymph node biopsy (SLNB) between 2007 and 2017 at the Erasmus Medical Centre Cancer Institute were eligible. The CP-GEP model combines clinicopathological features (age and Breslow thickness) with the expression of eight target genes involved in melanoma metastasis (ITGB3, PLAT, SERPINE2, GDF15, TGFBR1, LOXL4, CXCL8 and MLANA). Using the pathology result of SLNB as the gold standard, performance measures of the CP-GEP model were calculated, resulting in CP-GEP high risk or low risk for nodal metastasis. RESULTS: In total, 210 patients were included in the study. Most patients presented with T2 (n = 94, 45%) or T3 (n = 70, 33%) melanoma. Of all patients, 27% (n = 56) had a positive SLNB, with nodal metastasis in 0%, 30%, 54% and 16% of patients with T1, T2, T3 and T4 melanoma, respectively. Overall, the CP-GEP model had a negative predictive value (NPV) of 90·5% [95% confidence interval (CI) 77·9-96.2], with an NPV of 100% (95% CI 72·2-100) in T1, 89·3% (95% CI 72·8-96·3) in T2 and 75·0% (95% CI 30·1-95·4) in T3 melanomas. The CP-GEP indicated high risk in all T4 melanomas. CONCLUSIONS: The CP-GEP model is a noninvasive and validated tool that accurately identified patients with primary cutaneous melanoma at low risk for nodal metastasis. In this validation cohort, the CP-GEP model has shown the potential to reduce SLNB procedures in patients with melanoma.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Mulder EEAP, Dwarkasing JT, Tempel D, et al. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma. Br J Dermatol. 2020. PMID: 32844403. doi:10.1111/bjd.19499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。